Actinium Pharmaceuticals, Inc. (ATNM: NYSE MKT) is a public biopharmaceutical company specialized in the development of cancer drugs. The Company's product candidates are based on its patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence. ATNM's first drug for the treatment of acute myeloid leukemia (AML) has been administered to 49 patients with promising results and the second generation drug candidate is currently in clinical trials with 28 patients treated to date. In addition to leukemia drugs, ATNM's technology has been used to produce drug candidates for treatment of metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers) and bone marrow ablation, part of a curative treatment for leukemias, lymphomas and multiple myeloma.
Company intends to develop its products through Phase II clinical trials and it then intends to partner each drug for completion of development and commercialization with an appropriate third party. ATNM expects that its revenues will be derived from upfront payments, milestone payments and royalty payments, which payments comprise a standard structure of such partnering deals. In some markets, ATNM may seek to retain commercial rights and derive additional revenue from sales of its products.
ATNM's largest shareholder is AHLB Holdings, LLC, which is wholly owned by Memorial Sloan Kettering Cancer Center. ATNM's second largest shareholder is a subsidiary of Merck and Co.